<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01717924</url>
  </required_header>
  <id_info>
    <org_study_id>2011_25</org_study_id>
    <secondary_id>2012-000998-24</secondary_id>
    <nct_id>NCT01717924</nct_id>
  </id_info>
  <brief_title>Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma</brief_title>
  <acronym>ADCI002</acronym>
  <official_title>Multicenter Randomized Controlled Trial to Evaluate the Strategy of Primary Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma (ADCI002 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fédération de Recherche en Chirurgie (FRENCH)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ADCI 002 trial is a large multicenter phase II-III prospective randomized controlled
      trial comparing primary surgery versus primary chemotherapy followed by surgery in patients
      with a resectable signet ring cell gastric adenocarcinoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2012</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients dead in the 2-years</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival at 2 years</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival at 3 years</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 3 years</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>within 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>grade III/IV toxicity</measure>
    <time_frame>2 years</time_frame>
    <description>tolerance will be measured by the rate and grade of chemotherapy's complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post operative morbi-mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average of patients who benefit from the overall treatment strategy</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>emotional status</measure>
    <time_frame>2 years</time_frame>
    <description>It will be assessed by quality of life questionnaire(QLQ-C30, QLQ-STO-22,SF-36) and emotional status questionnaire(CES-D, STAI-Y-A, Brief-IPQ, WCC, ICEC-R, CRA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">314</enrollment>
  <condition>Signet Ring Cell Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>peri-operative chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant chemotherapy with 3 cycles of Epirubicin/Cisplatin/5 fluoro-uracil (oral or intra-veinous) Surgery within 3 and 6 weeks after the end of neoadjuvant chemotherapy Adjuvant chemotherapy with 3 cycles of the same chemotherapy within 6 and 12 weeks after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>surgery first with adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgery first Adjuvant chemotherapy with 3 cycles of Epirubicin/Cisplatin/5FU within 6 and 12 weeks after surgery No neoadjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peri-operative chemotherapy</intervention_name>
    <description>Usual treatment strategy for gastric adenocarcinoma</description>
    <arm_group_label>peri-operative chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery first</intervention_name>
    <description>strategy with a surgical procedure first, without the usual peri-operative chemotherapy</description>
    <arm_group_label>surgery first with adjuvant chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adenocarcinoma of the stomach or the oesogastric junction of type III of Siewert
             classification,histologically proven with the presence of signet ring cells (according
             to WHO 2000 classification) or diffuse form (according to Lauren classification) on
             pre-therapeutic biopsies

          -  tumoural stage IB, II or III (according to UICC-AJCC 2009)

          -  patient judged resectable in a curative intent on inclusion

          -  absence of distant metastasis

          -  absence of peritoneal carcinomatosis during pre-treatment explorative laparoscopy

          -  WHO performance status 2 or less

          -  age over 18 or under 80 years

          -  weight loss at the time of inclusion &lt; 15%

          -  neutrophilic polynuclears more than 1500/mm3

          -  platelets more than 100000/mm3

          -  creatinine clearance more than 50 ml/min

          -  serum-albumin more than 30 gram/l

          -  bilirubin less than 1,5 normal

          -  prothrombin rate over 80%

          -  absence of prior treatment with chemotherapy or radiotherapy for gastric cancer

          -  absence of kniwn child B or C cirrhosis

          -  left ventricular ejection fraction more than 50% before epirubicin treatment

          -  extension check-up performed within 4 weeks of inclusion

          -  signed written informed consent given by the patient

        Exclusion Criteria:

          -  no corresponding to the inclusion criteria

          -  another malignant tumour treated for curative purposes during the past 5 years
             excepted basocellular skin carcinoma or in situ uterine cervix cancer

          -  allergy to the active substance or one of the excipients in the study drugs

          -  pregnancy or breast-feeding

          -  any other concommitant treatment, immunotherapy or hormonal therapy

          -  history of abdominal or chest radiotherapy

          -  any evolving disorder which is not under control (liver failure, kidney failure,
             respiratory failure, evolving heart failure or myocardial necrosis during the past 6
             months)

          -  patients who cannot be regularly monitored
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>christophe mariette, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FFCD, FNCLCC, FRENCH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>christophe Mariette, MD,PhD</last_name>
    <phone>+33320444407</phone>
    <email>christophe.mariette@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>General and digestive surgical department, Claude Huriez Hospital, University Hospital</name>
      <address>
        <city>Lille cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>christophe mariette, MD,PhD</last_name>
      <phone>+33320444407</phone>
      <email>christophe.mariette@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>christophe mariette</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2012</study_first_submitted>
  <study_first_submitted_qc>October 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2012</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Signet ring cell</keyword>
  <keyword>gastric adenocarcinoma</keyword>
  <keyword>peri-operative chemotherapy</keyword>
  <keyword>surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

